Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912899 · ClinicalTrials.gov registry record · Phase 1
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cougar Biotechnology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00912899 is a Phase 1 study that was terminated before completion, run by Cougar Biotechnology. The registered enrollment target is 12 participants.
The verdict
NCT00912899, a Phase 1 study, was terminated before completion, sponsored by Cougar Biotechnology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
Interventions
- DRUG Noscapine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912899
The ClinicalTrials.gov registry entry for NCT00912899 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cougar Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Noscapine HCl is the first listed.
NCT00912899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00912899 about?
NCT00912899 is a clinical study titled "A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma". This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma
What is the current status of trial NCT00912899?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2007-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00912899?
The interventions under investigation include: Noscapine HCl (DRUG).
Who is sponsoring clinical trial NCT00912899?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.